LEXICON PHARMACEUTICALS, INC.
About LEXICON PHARMACEUTICALS, INC.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $49.8M
- Net income
- -$50.3M
- Total assets
- $185.0M
- Market cap
- $848.4M
- Gross margin
- 99.4%
- Operating margin
- -98.2%
- Net margin
- -101.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $49.8M
- Cost of revenue
- $274.0K
- Gross profit
- $49.5M
- Operating expenses
- $98.4M
- Operating income
- -$48.9M
- Net income
- -$50.3M
- EPS (basic)
- $-0.14
- EPS (diluted)
- $-0.14
Balance sheet
- Total assets
- $185.0M
- Current assets
- $101.9M
- Total liabilities
- $77.4M
- Current liabilities
- $20.9M
- Shareholders’ equity
- $107.5M
Cash flow
- Operating cash flow
- -$67.9M
- Investing cash flow
- $113.0M
- Financing cash flow
- -$48.5M
- Net cash flow
- -$3.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $848.4M
- EPS (diluted)
- $-0.14
- Shares outstanding
- 451.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 7, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $50.3M in FY2025.
- Revenue grew 16612% from FY2021 to FY2025.
- Gross margin of 99.4%, net margin -101.1%.
- Trading 23% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review LEXICON PHARMACEUTICALS, INC..
Write a review
News about LEXICON PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
